Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

FDA Approval of Mirdametinib Reduces Treatment Barriers for Adult Patients With NF1-Associated PNs

August 7th 2025

Timothy Gershon, MD, PhD, discusses how the FDA approval of mirdametinib will affect the treatment paradigm for adult patients with NF1-associated PNs.

ASCO Updates Living Guidelines to Include New Treatment Strategies for NSCLC With/Without Driver Alterations

August 7th 2025

ASCO updated their clinical practice guidelines for stage IV NSCLC with or without a driver alteration.

NCCN Adds LEMS Antibody Testing, Treatment Recommendations to Clinical Practice Guidelines in SCLC

August 7th 2025

The NCCN Clinical Practice Guidelines in Oncology for SCLC added new recommendations for LEMS, the use of amifampridine, and VGCC antibody testing.

Novel ADC Sigvotatug Vedotin Generates Early Efficacy in NSCLC

August 7th 2025

Rachel E. Sanborn, MD, discusses the novel IB6-directed ADC sigvotatug vedotin for the treatment of patients with NSCLC.

FDA Grants Priority Review to Liso-Cel for R/R Marginal Zone Lymphoma

August 4th 2025

The FDA granted priority review to a supplemental biologics license application for lisocabtagene maraleucel in relapsed/refractory marginal zone lymphoma.

Dr George on the Clinical Relevance of Targetable Mutations in GIST

August 4th 2025

Suzanne George, MD, discusses the evolving development of targeted therapies for patients with gastrointestinal stromal tumor.

Casdatifan Plus Cabozantinib Shows Early-Phase Efficacy in Clear Cell RCC

August 4th 2025

Rana R. McKay, MD, FASCO, discusses findings from the ARC-20 trial of casdatifan plus cabozantinib in pretreated clear cell renal cell carcinoma.

EMA Grants Orphan Drug Designation to Nuvisertib for Myelofibrosis

August 2nd 2025

Nuvisertib has received orphan drug designation from the EMA for patients with myelofibrosis.

China’s NMPA Accepts sNDA for Ivonescimab Plus Chemotherapy in Frontline Advanced Squamous NSCLC

July 31st 2025

Ivonescimab plus chemotherapy is under review in China for the frontline treatment of patients with advanced squamous non–small cell lung cancer.

First-Line Onvansertib Plus Bevacizumab and Chemo Yields Responses in RAS-Mutated mCRC

July 30th 2025

Onvansertib plus SOC generated responses with a tolerable safety profile in patients with previously untreated RAS-mutated metastatic colorectal cancer.

Namodenoson Surpasses Halfway Enrollment Benchmark in Advanced Pancreatic Cancer Trial

July 30th 2025

Can-Fite has reached the over 50% enrollment milestone for an ongoing phase 2a trial evaluating namodenoson in pancreatic cancer.

Knowledge of Unique ADC-Related Toxicities Is Critical for Safe, Effective Use in NSCLC

July 28th 2025

Corey J. Langer, MD, FACP, provides a focused overview of antibody-drug conjugate–related toxicities and AE management in lung cancer.

How Multiomics and Artificial Intelligence Are Transforming Localized NSCLC: A Deep Dive

July 28th 2025

Sandip Patel, MD, explores how AI and multiomics are transforming localized non–small cell lung cancer care.

Cellular Therapies Begin to Make Their Mark in Solid Tumors

July 24th 2025

OncLive spoke with experts working to develop cellular therapies in solid tumors to gain insights into their current standing and future in the space.

Inavolisib Plus Palbociclib/Fulvestrant Gains European Approval in PIK3CA-Mutant, HR+/HER2– Advanced Breast Cancer

July 23rd 2025

The European Commission has approved inavolisib plus palbociclib/fulvestrant in PIK3CA-mutant ER-positive, HER2-negative advanced breast cancer.

Subcutaneous Daratumumab Receives European Commission Approval in Smoldering Myeloma

July 23rd 2025

Subcutaneous daratumumab received EU approval for the treatment of patients with smoldering multiple myeloma at high risk of developing multiple myeloma.

European Commission Approves Ibrutinib in Treatment-Naive, Transplant-Eligible MCL

July 23rd 2025

Ibrutinib has received an expanded indication from the European Commission for the treatment of patients with newly diagnosed MCL eligible for transplant.

Zidesamtinib Is Set to Overcome the Limitations of Current ROS1 TKIs in ROS1+ NSCLC

July 22nd 2025

Joshua K. Sabari, MD, discusses the design of the phase 1/2 ARROS-1 study, as well as key efficacy data with zidesamtinib in ROS1 fusion–positive NSCLC.

Dr Sabari on Efficacy of Zidesamtinib in TKI-Pretreated, Advanced, ROS1+ NSCLC

July 18th 2025

Joshua K. Sabari, MD, discusses response rates observed with zidesamtinib in patients with advanced ROS1-positive non–small cell lung cancer.

Luspatercept Plus Concomitant JAK Inhibitor Therapy Misses Primary End Point in Myelofibrosis-Associated Anemia

July 18th 2025

Luspatercept plus a concomitant JAK inhibitor didn’t meet the primary end point of 12-week RBC transfusion independence in myelofibrosis-associated anemia.